A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease

QR kód

A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease

The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the...

Teljes leírás

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Farkas Klaudia Molnár Tamás
Dokumentumtípus:	Cikk
Megjelent:	2018
Sorozat:	IMMUNOTHERAPY 10 No. 2
doi:	10.2217/imt-2017-0107
mtmt:	3298537
Online Access:	http://publicatio.bibl.u-szeged.hu/15422

Hasonló tételek

Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases a prospective; multicentre; nationwide cohort /
Szerző: Gecse Krisztina Barbara, et al.
Megjelent: (2016)

Switching from infliximab to biosimilar in inflammatory bowel disease
Szerző: Milassin Ágnes, et al.
Megjelent: (2019)

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases results from Central European nationwide cohort /
Szerző: Bálint Anita, et al.
Megjelent: (2017)

Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis
Szerző: Farkas Klaudia, et al.
Megjelent: (2016)

Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients
Szerző: Bacsur Péter, et al.
Megjelent: (2022)

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /
Szerző: Sarlós Patrícia, et al.
Megjelent: (2023)

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
Szerző: Farkas Klaudia, et al.
Megjelent: (2015)

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center
Szerző: Farkas Klaudia, et al.
Megjelent: (2017)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
Szerző: Bor Renáta, et al.
Megjelent: (2017)

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
Szerző: Pallagi-Kunstár Éva, et al.
Megjelent: (2014)

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study
Szerző: Lontai Livia, et al.
Megjelent: (2022)

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort
Szerző: Bálint Anita, et al.
Megjelent: (2018)

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.
Szerző: Iliás Ákos, et al.
Megjelent: (2019)

Outcomes of treatment cessation afterswitching to subcutaneous vedolizumab treatment in inflammatory bowel diseases
Szerző: Bacsur Péter, et al.
Megjelent: (2024)

Lupus-like reactions in patients with inflammatory bowel disease
Szerző: Pigniczki Daniella, et al.
Megjelent: (2019)

Iron Deficiency Anemia in Inflammatory Bowel Disease What Do We Know? /
Szerző: Resál Tamás, et al.
Megjelent: (2021)

Spotlight on Transition in Patients With Inflammatory Bowel Disease A Systematic Review /
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Szerző: Gordon Hannah, et al.
Megjelent: (2023)

Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria
Szerző: Ferenczi Szilamér, et al.
Megjelent: (2021)

Crucial steps for treatment optimization and decision making in inflammatory bowel disease management
Szerző: Szántó Kata Judit
Megjelent: (2023)

Advanced treatment options of inflammatory bowel diseases after anti-TNF failure
Szerző: Bacsur Péter
Megjelent: (2025)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
Szerző: Dulic Sonja, et al.
Megjelent: (2020)

Inflammatory Bowel Disease and Physical activity a study on the impact of diagnosis on the level of exercise amongst patients with IBD /
Szerző: Gatt K., et al.
Megjelent: (2019)

Improving disease management of patients with inflammatory bowel disease the potential role of self-concordant health goals /
Szerző: Horvát Barbara, et al.
Megjelent: (2023)

Importance of Diet in Inflammatory Bowel Disease – Data from the Patients’ View
Szerző: Molnár Tamás, et al.
Megjelent: (2014)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
Szerző: Bacsur Péter, et al.
Megjelent: (2023)

Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease
Szerző: Ellul Pierre, et al.
Megjelent: (2023)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
Szerző: Szántó Kata Judit, et al.
Megjelent: (2021)

Adverse events associated with management of inflammatory bowel diseases infections and side effects /
Szerző: Bálint Anita
Megjelent: (2015)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases A European retrospective observational study /
Szerző: Goessens Laurent, et al.
Megjelent: (2021)

The Role of Gut Permeability and Serine-Proteases in the Pathomechanism of Irritable Bowel Syndrome and Inflammatory Bowel Diseases
Szerző: Gecse Krisztina
Megjelent: (2012)

Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease An ECCO CONFER Multicentre Case Series /
Szerző: Festa Stefano, et al.
Megjelent: (2022)

New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents Cyclosporine Plus Vedolizumab /
Szerző: Szántó Kata Judit, et al.
Megjelent: (2018)

Enhancing self-management of patients with inflammatory bowel disease the role of autonomy support in health goal pursuit /
Szerző: Horvát Barbara, et al.
Megjelent: (2024)

Sarcopenia as an independent predictor of the surgical outcomes of patients with inflammatory bowel disease
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

Advances in Gut Microbiota Functions in Inflammatory Bowel Disease Dysbiosis, Management, Cytotoxicity Assessment, and Therapeutic Perspectives /
Szerző: Kushkevych Ivan, et al.
Megjelent: (2025)

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
Szerző: Sánta Anett, et al.
Megjelent: (2023)

Barriers in inflammatory bowel disease care in Central and Eastern Europe a region-specific analysis /
Szerző: Prokopič Michal, et al.
Megjelent: (2023)

Effect of genetical, environmental and clinical factors on the aetiology and natural course of inflammatory bowel disease
Szerző: Molnár Tamás
Megjelent: (2002)

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
Szerző: Mandel Michael D., et al.
Megjelent: (2014)